There is no FDA-approved cagrilintide-plus-tirzepatide combination product, and no published clinical trials have tested this specific pairing at defined doses. Cagrilintide is an investigational long-acting amylin analog developed by Novo Nordisk; tirzepatide is Eli Lilly’s dual GLP-1/GIP agonist sold as Mounjaro for type 2 diabetes and Zepbound for obesity. Novo Nordisk’s combination program pairs cagrilintide with its own semaglutide, not with tirzepatide. Anyone planning to “stack” cagrilintide with tirzepatide outside a clinical trial is doing so without established safety or dosing evidence and without legal access to the investigational drug.
What Each Drug Does
Cagrilintide
Cagrilintide is a synthetic, long-acting analog of amylin, a peptide hormone the pancreas co-secretes with insulin. Amylin slows gastric emptying, suppresses glucagon after meals, and produces satiety signals in the brain. Cagrilintide is dosed weekly in clinical trials and remains investigational — it is not FDA-approved for any indication as of 2026.
Tirzepatide
Tirzepatide activates both the GLP-1 and GIP receptors. It is FDA-approved as:
- Mounjaro: type 2 diabetes (2022)
- Zepbound: chronic weight management in obesity (2023), and obstructive sleep apnea with obesity (2024)
See our guide on Zepbound for diabetes for more on tirzepatide’s labels.
The Combination That Actually Exists: CagriSema
Novo Nordisk developed CagriSema — cagrilintide plus semaglutide — as a combination injectable for obesity. The REDEFINE trial program tested dose-matched combinations and reported meaningful additive weight loss compared with semaglutide alone. Specific trial-reported doses have varied (for example, cagrilintide 2.4 mg plus semaglutide 2.4 mg weekly in REDEFINE-1). Results have been encouraging, though not as dramatic as some early projections, and the product is not yet FDA-approved.
Key point: CagriSema data is about cagrilintide + semaglutide, not cagrilintide + tirzepatide. Extrapolating from one to the other is speculative.
Why There Is No Published Cagrilintide + Tirzepatide Data
- Cagrilintide is Novo Nordisk’s proprietary molecule; tirzepatide is Eli Lilly’s. Combination trials across competitor companies are rare.
- Each company is pursuing its own next-generation combination (Novo: CagriSema; Lilly: retatrutide, a triple GLP-1/GIP/glucagon agonist).
- Cagrilintide alone is still finishing its regulatory process; pairing it with a competitor’s drug would complicate both filings.
What About “Stacking” Online?
Some online communities and unregulated compounding sellers have promoted “stacking” cagrilintide with tirzepatide. Reasons to be cautious:
- Legal access: cagrilintide is an investigational drug; purchasing it outside a clinical trial is not legal in the US and the product is not FDA-approved.
- Product identity: products labeled “cagrilintide” sold by research-chemical sellers or unregulated pharmacies cannot be verified for identity, purity, or sterility.
- Dose uncertainty: dosing schedules used in trials are specific to trial protocols and cannot be directly copied to a different-molecule partner like tirzepatide.
- Side-effect additivity: GI side effects (nausea, vomiting, delayed gastric emptying) are likely additive; so is pancreatitis risk.
- Contamination: non-regulated peptide supplies have historically carried contamination risk.
What Clinical-Trial Doses Have Been Used
For reference — not a recommendation — published trials of cagrilintide alone and CagriSema combinations have tested:
| Regimen | Cagrilintide Dose | Partner Drug | Notes |
|---|---|---|---|
| Cagrilintide monotherapy (early trials) | Titrated up to 2.4 mg weekly | None | Phase 2 obesity data |
| CagriSema (REDEFINE-1) | 2.4 mg weekly | Semaglutide 2.4 mg weekly | Additive weight loss vs semaglutide alone |
| CagriSema (REDEFINE-2) | 2.4 mg weekly | Semaglutide 2.4 mg weekly | Obesity with type 2 diabetes population |
| Cagrilintide + tirzepatide | No FDA- or peer-reviewed trial data | Not studied | Not a validated combination |
These numbers do not give you a dosing recipe. They establish that doses used in well-monitored trials with semaglutide may not transfer to tirzepatide, a different drug with a different tolerability profile.
Safer Paths to More Weight Loss on Tirzepatide
If tirzepatide alone is producing less weight loss than hoped, safer options that stay within regulated care include:
- Confirm you are on the right dose and that titration is complete (2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg weekly)
- Tighten food quality — a Mediterranean-style, lower-glycemic-load pattern
- Add resistance training to preserve muscle while losing fat
- Optimize sleep, stress, and treat any sleep apnea
- Address alcohol intake (slows fat loss substantially)
- Reassess medications that cause weight gain (some antidepressants, antipsychotics, corticosteroids)
- Consider bariatric surgery consultation for severe obesity
See our guides on reversing prediabetes and reducing insulin resistance for broader context.
When Will Real Combination Data Arrive?
If Novo Nordisk advances CagriSema through phase 3 and into FDA approval, that would be the first approved cagrilintide-containing combination — paired with semaglutide, not tirzepatide. Separately, Eli Lilly’s retatrutide is a triple-agonist in development that addresses the same unmet need (stronger weight loss) without adding a second injection. Expect clearer answers in the 2026 to 2028 window as these programs report pivotal data.
The Bottom Line
There is no published cagrilintide-plus-tirzepatide combination data at defined doses, and no FDA-approved product pairs them. CagriSema pairs cagrilintide with semaglutide, not tirzepatide. Self-stacking research compounds with FDA-approved drugs is not safe, not legal in the US outside of clinical trials, and not supported by real evidence. If you are already on tirzepatide and want better results, work with your clinician on dose, lifestyle, and other approved strategies rather than adding unapproved peptides from unverified sources.
